Advisory Council

Victor Tetz, MD, PhDGeorge Tetz, MD, PhDRita Shaknovich, MD, PhDMichael Cynamon, MD

Dr. V. Tetz is the founder and chairman, and currently serves as Scientific Advisor and is responsible for the strategic planning of the Human Microbiology Institute, a not-for-profit scientific research organization dedicated to advancing our understanding of the human microbiota, which plays a role in human health, diseases, and lifespan. Prior to founding HMI, Victor successfully worked in senior positions in research and drug development companies. A member of the American Society for Microbiology, Dr. V. Tetz is regarded as one of the leading microbiologists of the 21st century for his numerous invaluable practical and theoretical contributions to microbiological research.

Dr. V. Tetz has been in the background of numerous groundbreaking studies in the fields of microbiology and virology aimed at discovering novel regulation pathways in microbial communities, particularly within the human microbiota; discovering novel bacterial species, including several whose role in cancer is now under review; the development of novel theoretical concepts that have led to the reevaluation of the accepted causes of many diseases; the discovery of new human pathologies.

Dr. V. Tetz is also a Senior Investigator and Group Leader in Microbiology Research for a company conducting research for Pepsi, Gen3Partners, Dole, and others. He also stands at the origin of the revolutionary drug candidates Mul-1867 and rhDNase.

Mul-1867 is a first-in-class broad spectrum antimicrobial that is active against antibiotic-resistant bacterial, fungal, and mixed infections, which was developed by TGV-inhalonix and TGV-Therapeutics. The primary indications for this antimicrobial are for the treatment of respiratory tract infections in cystic fibrosis, COPD, and age-related pneumonia patients, etc.

rhDNase is a recombinant human deoxyribonuclease I (rhDNase I), and is a proprietary product candidate for the prevention or treatment of graft versus host diseases GVHD. Meanwhile, rhDNase is currently under development by SCIVAC-OPK for drug translation. rhDNase is a recombinant human deoxyribonuclease I (rhDNase I), and is a proprietary product candidate for the prevention or treatment of graft versus host diseases GVHD.

In total, Dr. V. Tetz has over 45 years of experience in microbiological research and drug discovery.

IMG_4155+

Dr. G. Tetz is the founder and chairman of Human Microbiology Institute.

Dr. G. Tetz has been in the background of numerous groundbreaking studies in the fields of microbiology and virology aimed at discovering novel regulation pathways in microbial communities, particularly within the human microbiota; discovering novel bacterial species, including several whose role in cancer is now under review; the development of novel theoretical concepts that have led to the reevaluation of the accepted causes of many diseases; the discovery of new human pathologies.

Dr. G. Tetz also played a critical role in the origin of the revolutionary drug candidates Mul-1867 and rhDNase.

Mul-1867 is a first-in-class broad spectrum antimicrobial that is active against antibiotic-resistant bacterial, fungal, and mixed infections, which was developed by TGV-inhalonix and TGV-Therapeutics. The primary indications for this antimicrobial are for the treatment of respiratory tract infections in cystic fibrosis, COPD, and age-related pneumonia patients, etc.

rhDNase is a recombinant human deoxyribonuclease I (rhDNase I), and is a proprietary product candidate for the prevention or treatment of graft versus host diseases GVHDMeanwhile, rhDNase is currently under development by SCIVAC-OPK for drug translation. rhDNase is a recombinant human deoxyribonuclease I (rhDNase I), and is a proprietary product candidate for the prevention or treatment of graft versus host diseases GVHD.

In total, Dr. G. Tetz has over 16 years of experience in microbiological research and drug discovery. He is currently a member of the American Chemical Society and the American Society for Microbiology.

Dr. R.Shaknovich is a physician scientist with strong interests in cancer biology and translational research.

My clinical expertise is in Oncologic Pathology with the focus on Hematologic malignancies. My research training was focused on cancer in general and on hematologic malignancies in particular from the time of my PhD, investigating function of PLZF-RAR fusion protein in Acute Promyelocytic Leukemia.

Dr. R.Shaknovich has extensive experience in human and mouse pathology, assessment of mouse models of cancer, experimental therapeutics and immunology.  My research focuses on epigenetics of normal B cell development and lymphomagenesis, immunobiology and clonal cancer heterogeneity utilizing many experimental and computational tools that allow genome-wide profiling of DNA methylation and gene expression.

 

m. Cynamon

 

Dr. Michael Cynamon is nationally known for his infectious disease research.

Dr. Michael Cynamon is a leading researcher in pulmonary infections with more than 35 years experience in healthcare research.

The primary areas of expertise include antimicrobial resistance and